Previous Article | Next Article 
Journal of Virology, September 2000, p. 7878-7883, Vol. 74, No. 17
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Sequence Variability of Borna Disease Virus: Resistance to
Superinfection May Contribute to High Genome Stability in
Persistently Infected Cells
Stephan
Formella,
Christian
Jehle,
Christian
Sauder,
Peter
Staeheli, and
Martin
Schwemmle*
Department of Virology, Institute for Medical
Microbiology and Hygiene, University of Freiburg, D-79104 Freiburg,
Germany
Received 4 February 2000/Accepted 8 June 2000
 |
ABSTRACT |
The RNA genome of Borna disease virus (BDV) shows extraordinary
stability in persistently infected cell cultures. We performed bottleneck experiments in which virus populations from single infected
cells were allowed to spread through cultures of uninfected cells and
in which RNase protection assays were used to identify virus variants
with mutations in a 535-nucleotide fragment of the M-G open reading
frames. In one of the cell cultures, the major virus species
(designated 2/1) was a variant with two point mutations in the G open
reading frame. When fresh cells were infected with a low dose of a
virus stock prepared from 2/1-containing cells, only a minority of the
resulting persistently infected cultures contained detectable levels of
the variant, whereas the others all seemed to contain wild-type virus.
The BDV variant 2/1 remained stable in the various persistently
infected cell cultures, indicating that the cells were resistant to
superinfection by wild-type virus. Indeed, cells persistently infected
with prototype BDV He/80 were also found to resist superinfection with
strain V and vice versa. Our screen for mutations in the viral M and G
genes of different rat-derived BDV virus stocks revealed that only one
of four stocks believed to contain He/80 harbored virus with the
original sequence. Two stocks mainly contained a novel virus variant
with about 3% sequence divergence, whereas the fourth stock contained
a mixture of both viruses. When the mixture was inoculated into the
brains of newborn mice, the novel variant was preferentially amplified.
These results provide evidence that the BDV genome is mutating more
frequently than estimated from its invariant appearance in persistently
infected cell cultures and that resistance to superinfection might
strongly select against novel variants.
 |
INTRODUCTION |
Genome replication of RNA viruses is
error prone, because RNA-dependent RNA polymerases lack proofreading
activity (10, 18). Nevertheless, field isolates of certain
RNA viruses exhibit a high degree of genetic stability over many
decades (10). The selective forces which restrict virus
variability are presumably complex and nonuniform. In most cases, the
mechanisms of restriction are largely unknown.
Borna disease virus (BDV) is a newly classified nonsegmented
negative-strand RNA virus that can persistently infect the central nervous systems of a broad range of warm-blooded animals and possibly humans without destruction of its host cells (11, 13, 21, 29). Natural and experimental infections with BDV usually result in immune-system-mediated neurological disease and behavioral abnormalities (5, 13, 14, 34). Sequence comparisons between old and recent BDV isolates of diseased animals from regions of endemicity in Central Europe revealed viral genome conservation of
greater than 95%, in spite of the fact that some of these viruses were
passaged many times in experimental animals or in cell culture (3,
28). Recent evidence indicates that BDV strains from outside the
classical regions of endemicity (e.g., Japan, Sweden, and the United
States) (1, 2, 7, 11, 19) are virtually identical (95 to
98% identity) to the Central European strains (3, 28).
However, we recently characterized a novel field isolate from a
diseased horse in eastern Austria whose genome was only about 85%
identical to that of classical BDV strains, demonstrating that BDV can
easily tolerate more nucleotide exchanges (22).
Intriguingly, the nucleotide exchanges of the novel BDV isolate have
little effect on the primary structures of most viral proteins
(22).
To elucidate the molecular basis of the high stability of the BDV
genome in persistently infected cells, we tested the hypothesis that
virus mutants are constantly present but fail to emerge under standard
conditions. We report the successful amplification of a novel virus
mutant by creating bottleneck conditions under which virus populations
of single infected cells were allowed to spread to uninfected cells
that were provided in large excess. We propose that the observed
resistance of BDV-infected cells to superinfection with BDV variants
contributes to viral genome stability. Analysis of laboratory strains
further showed that they can undergo dynamic changes during passage in
the brains of animals and that new virus variants can eventually become
dominant in the population.
 |
MATERIALS AND METHODS |
Infection of cell cultures.
Single rat astroglia cells (C6
cells) from a cell culture persistently infected with BDV strain He/80
(6) were seeded in 96-well dishes. After adherence,
approximately 400 uninfected C6 cells were added. After the cells had
grown to confluency, passages were done at a ratio of 1:5 for 3 to 4 weeks. The degree of virus infection of the cultures was determined by
indirect immunofluorescence assay (IFA) as described previously
(16) using a polyclonal serum directed against the viral
phosphoprotein (31). Standard virus infections were carried
out with 105 C6 cells and various amounts of virus stocks
in the presence of culture medium containing 10% fetal calf serum
(FCS). Cells infected with high doses (approximately 100, 500, 2,500, and 10,000 focus-forming units [FFU]) of BDV virus stock derived from
2/1-containing cells were passaged at a ratio of 1:5 for 3 to 4 weeks.
Preparation of total RNA.
Total RNA of either BDV-infected
C6 cells or the brains of neonatally infected rats and mice harvested
at 4 weeks postinfection were prepared using peqGOLD TriFast (Peqlab)
according to the manufacturer's recommendations. The precipitated RNA
samples were dissolved in water.
In vitro transcription and RPA.
Runoff transcriptions were
performed with 0.2 µg of EcoRI-linearized plasmid pRPAwt
(20) in a total volume of 20 µl of T7 transcription buffer
(Roche Molecular Biochemicals) containing 28 U of RNasin (Amersham);
0.5 µM (each) ATP, GTP, and CTP; 0.05 µM UTP (Pharmacia); 3 U of T7
RNA polymerase (MBI Fermentas); and 10 µCi of 32P-labeled
UTP (3,000 Ci/mmol; Amersham). After incubation at 37°C for 90 min,
the total volume was raised to a final volume of 30 µl with
transcription buffer including 4 U of RNase-free DNase (Ambion) and
incubated for a further 30 min at 37°C to digest plasmid DNA.
Purification of the 32P-labeled RNA and subsequent RNase
protection assay (RPA) reactions were carried out as described
previously (32) using approximately 1.4 × 105 cpm of 32P-labeled RPA probe and 10 µg of
total RNA per sample. The digestion of unhybridized RNA involved 16 U
of RNase T1 (Ambion)/sample and either 0.02 or 4 µg of
RNase A (Roche Molecular Biochemicals).
Virus stocks.
Virus stocks from C6 cells persistently
infected with BDV strain He/80 (6) were prepared as
described previously (4) with slight modifications. Briefly,
25 confluent 90-mm-diameter plates were washed with 20 mM HEPES (pH
7.4) and incubated with 10 ml of 20 mM HEPES (pH 7.4) containing 250 mM
MgCl2 and 1% FCS for 1.5 h at 37°C. Subsequently,
the virus-containing supernatants were harvested and centrifuged twice
at 2,500 × g for 5 min to remove cell debris. The
virus particles were concentrated by ultracentrifugation for 1 h
at 20°C and 80,000 × g onto a 20% sucrose cushion
containing 10 mM HEPES (pH 7.4) and 0.5% FCS. The virus-containing
pellets were finally resuspended in phosphate-buffered saline.
Titration of BDV using Vero cells was performed as described previously (17).
The following virus stocks from He/80-infected rats were used in this
study: no. 66, fifth passage in brains of newborn Lewis rats (a gift
from L. Stitz, Tübingen, Germany); no. 62, fifth passage in
brains of adult Lewis rats (a gift from L. Stitz); no. 61, fifth
passage in brains of newborn Lewis rats (the fourth passage of this
virus was a gift from L. Stitz, whereas the fifth passage was done
locally as described below); and no. 102, third brain passage in
newborn Lewis rats (a gift of K. Carbone, Rockville, Md.), passaged
once in the brain of an adult Lewis rat. The last virus stock was only
available as an archival RNA sample (27).
Animal infections.
Newborn
2m0/0 MRL mice
were infected by the intracerebral route with 10 µl of rat
brain-derived virus stock no. 61, corresponding to approximately 500 FFU, in the thalamic region of the left hemisphere using a Hamilton
syringe as described previously (15). Four weeks
postinfection, successful infections of the mice were confirmed by
analyzing the total RNA of the brains by RPA. Virus stock no. 61 was
prepared from the brains of 4-week-old Lewis rats that were
intracerebrally infected neonatally with about 103 FFU of BDV.
Direct sequencing of RT-PCR products.
First-strand cDNA
synthesis was carried out with 4 µg of total RNA and He/80-specific
primer 1908F (5'-TCCTATGTGGAGCTCAAGGAC-3') in a final volume
of 20 µl using Superscript RT (Gibco Life Technologies) as
recommended by the manufacturer. Subsequent nested PCR (two series of
30 cycles as follows: 95°C, 1 min; 55°C, 1 min; 72°C, 1 min) was
carried out in a total volume of 100 µl containing 5 U of
Taq polymerase (Roche Molecular Biochemicals) using primers 2550R (5'-CTTAACAGTACCAGTGTACCG-3') and 1908F as the first
primer set and 2530R (5'-GATTGATGATCGGTCAGCG-3') and 1925F
(5'-GACAAGGTAATCGTCCCTGG-3') as the second primer set. The
first PCR mixture contained 2 µl of the reverse transcription (RT)
reaction mixture, whereas the second PCR mixture contained 5 µl of
the first PCR mixture. Amplification products were gel purified and
directly sequenced (Toplab).
Nucleotide sequence accession numbers.
Partial nucleotide
sequences of variant 2/1 and virus stocks no. 102 and 62 were deposited
in GenBank under accession no. AJ271120, AJ271118, and AJ250177, respectively.
 |
RESULTS |
Detection of sequence variations among different BDV strains by
RPA.
To ensure that RPA is a reliable method to identify small
nucleotide differences between closely related BDV strains, total RNA
of C6 cells infected with BDV strains He/80 and V were analyzed using
an RNA probe complementary to the coding sequence of the M and G
proteins (nucleotides [nt] 1975 to 2510) of He/80. Within this
region, the two strains differ at 22 nucleotide positions. At low
concentrations of RNase A (0.02 µg), the expected unspliced and three
spliced viral transcripts of He/80 were detected (Fig. 1, lane 4). When RNA of cells infected
with strain V was used, additional bands appeared (Fig. 1, lane 6). A
200-fold-increased RNase A concentration (4 µg) did not significantly
change the RPA signal pattern observed with He/80 transcripts (Fig. 1,
lane 5). However, pronounced degradation of the RPA probe was evident when strain V-derived RNA was analyzed (Fig. 1, lane 7), indicating that the mismatches of strain V transcripts are efficiently recognized. Thus, under stringent conditions, RPA can be used as a diagnostic tool
to identify sequence variations among BDV strains. All further RPA
experiments were therefore carried out with high concentrations of RNase A. It should be noted that due to the nucleotide
specificities of the RNases used in the assay, unpaired A residues were
not recognized.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 1.
RPA for the detection of sequence variations between
different strains of BDV. Nucleotide differences between the BDV
strains He/80 and V were visualized by RPA using a 535-nt RNA probe
(lane 1) complementary to the M and G open reading frames of strain
He/80. Analysis was carried out using 10 µg of tRNA (lane 2), RNA
samples (10 µg) prepared from total cell lysates of uninfected
(uninf.) C6 cells (lane 3), C6 cells infected with BDV strain He/80
(lanes 4 and 5), or C6 cells infected with BDV strain V (lanes 6 and
7). Low (0.02-µg) or high (4-µg) concentrations of RNase A were
used (+) as indicated. The repertoire of RNA species and the expected
gel positions of the corresponding RPA signals are indicated on the
right. The arrows mark signals resulting from RNA species with slightly
different sequences. The numbers to the left indicate the mobility of
molecular size markers (in nucleotides).
|
|
Characterization of a new BDV variant from persistently infected
cells.
Based on the hypothesis that a certain percentage of cells
within a population of BDV-infected cells may harbor virus variants in
addition to wild-type virus, we speculated that cocultivation of
uninfected cells with a single BDV-infected cell might allow the
characterization of such variants. To test this hypothesis, we seeded
uninfected C6 cells onto a single He/80-infected C6 cell to allow the
spread of virus to neighboring cells. Monitoring of infection by
indirect IFA indicated that after 3 to 4 weeks of passaging, 50 to 90%
of the cells were infected with BDV (data not shown). Subsequent RPA
screening using total RNA of 30 independent infected C6 cell cultures
revealed that one culture contained a BDV variant (designated 2/1), as
indicated by a dramatic change in the signal pattern (Fig.
2A, lane 5). To confirm this observation we determined the nucleotide sequence of the variant by sequencing nested RT-PCR amplification products corresponding to the M-G coding
sequence (nt 1975 to 2510). Two nucleotide changes were identified in
2/1 at positions 2433 and 2435 compared to He/80 (Fig. 2B), one of
which resulted in a nonconservative change of isoleucine to threonine
at position 67 of the G protein.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 2.
Identification of a new variant of BDV He/80. (A)
Samples of total RNA (10 µg) from a standard C6 cell culture
persistently infected with BDV He/80 (lane 4) or from newly established
persistently infected C6 cell cultures each initially infected with a
single He/80-infected C6 cell (lanes 5 to 8) were analyzed by RPA as
for Fig. 1, using high concentrations of RNase A. Note the novel signal
pattern of the virus in culture 2/1. Undigested RPA probe (lane 1). No
specific products were observed when the RPA was carried out with 10 µg of tRNA (lane 2) or 10 µg of total RNA from uninfected C6 cells
(lane 3). (B) Fragments of the M-G open reading frames (nt 1975 to
2510) of standard virus (He/80) and variant 2/1 were amplified by
RT-PCR, and their sequences were compared. The two T-to-C mutations
found in 2/1 (shaded) and the resulting amino acid change in the G open
reading frame (I67T [circled]) are indicated.
|
|
Closer inspection of the RPA signal pattern of 2/1-infected cells (Fig.
2A, lane 5) showed a weak pattern of protected bands
similar to that of
wild-type He/80, in addition to 2/1-specific
signals. To determine
whether a He/80-like virus was still present
in the cell culture, 10 C6
cell cultures were independently infected
with less than 10 FFU of a
virus stock prepared from 2/1-infected
cells as described in Materials
and Methods. Screening for BDV
by RPA 3 weeks postinfection revealed
that 7 out of 10 independent
cultures contained predominantly the
wild-type-like virus (Fig.
3A, lanes 6 to
8 and 12 to 15). Two cultures were persistently
infected with a mixture
of the He/80-like strain and 2/1, as judged
by the intensities of the
various signals (Fig.
3A, lanes 9 and
10), whereas one culture seemed
to be infected with the 2/1 variant
only (Fig.
3A, lane 11). However,
longer exposure of the film
showed that the He/80-like strain was still
present in this culture
(Fig.
3B, lane 11). The signal intensities
observed by RPA differed
strongly between 2/1- (Fig.
3A, lanes 9 to 11)
and He/80-infected
cells (Fig.
3A, lanes 6 to 8 and 12 to 15), although
equal amounts
of total RNA were used for analysis, indicating that the
absolute
amounts of viral transcripts were lower in cell cultures
infected
with 2/1. Consistent with these findings, the percentages of
infected
cells at 3 weeks postinfection, as determined by IFA, were
higher
than 50% in cell cultures predominantly infected with the
He/80-like
virus and less than 20% in cell cultures predominantly
infected
with 2/1 (data not shown), indicating that the efficiencies of
virus spread in these cultures differed.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
Nonuniform nature of BDV variant 2/1. (A) Samples of
total RNA (10 µg) from a standard C6 cell culture persistently
infected with BDV He/80 (lane 4), cell culture 2/1 (lane 5), and newly
established persistently infected C6 cell cultures infected with a low
dose (<10 FFU) of a BDV stock prepared from cell culture 2/1 (lanes 6 to 15) were analyzed by RPA as for Fig. 1. Note that the signal
patterns of most cultures differed from that of cell culture 2/1,
indicating that several virus variants were present. Undigested RPA
probe (lane 1). No specific products were observed when the RPA was
carried out with 10 µg of tRNA (lane 2) or 10 µg of total RNA from
uninfected C6 cells (lane 3). (B) Longer exposure of lanes 10 and 11 shown in panel A.
|
|
Cells persistently infected with BDV are resistant to
superinfection with other BDV strains.
The virus populations in
cell cultures derived from the bottleneck experiment remained stable
after persistent infection was established, as judged from the
unchanged RPA signal patterns (data not shown). Resistance of
BDV-infected cells to superinfection by other BDV variants could
explain this behavior. To test this hypothesis, C6 cells persistently
infected with the BDV strain He/80 were incubated with increasing doses
of strain V virus stocks. In parallel, uninfected C6 cells were
infected with the lowest dose of strain V virus used for the
superinfection experiment. Three weeks postinfection, almost all cells
of the entire control culture contained viral antigen, as determined by
indirect IFA (data not shown). RPA confirmed the infection of these
cells by BDV strain V (Fig. 4, lane 4).
Since strain V-specific RPA signals were absent from the other
cultures, we concluded that cells persistently infected with He/80
could not be infected with strain V under these conditions, independent
of the initial dose of virus used (Fig. 4, lanes 5 to 7). A similar
resistance to superinfection with BDV strain He/80 was observed in C6
cells persistently infected with strain V (Fig. 4, lanes 9 to 11) or
2/1 (data not shown).

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 4.
BDV-infected cells are resistent to superinfection. C6
cell lines persistently infected with either strain He/80 (lanes 5 to
7) or strain V (lanes 9 to 11) were incubated with various doses (100, 500, and 2,500 FFU) of partially purified BDV strain V (lanes 5 to 7)
or with various doses (40, 200, and 4,000 FFU) of partially purified
BDV strain He/80 (lanes 9 to 11). To control for the quality of the
virus stocks, uninfected C6 cells were infected with 100 FFU of strain
V (lane 4) or with 40 FFU of strain He/80 (lane 8). Three weeks
postinfection, when almost all cells in the control cultures were
expressing viral antigen, samples of total RNA (10 µg) from the
various cultures were analyzed by RPA as for Fig. 1, using high
concentrations of RNase A. Undigested RPA probe (lane 1). No specific
products were observed when the RPA was carried out with 10 µg of
tRNA (lane 2) or 10 µg of total RNA from uninfected C6 cells (lane
3).
|
|
Unexpected diversity of He/80 virus stocks with different passage
histories.
To evaluate the genome stability of BDV in vivo, we
used RPA to screen stocks of He/80 with different passage histories in rat brains for mutations in the viral M and G genes. RNA of C6 cells
infected with BDV stock no. 66 or no. 62 (Fig.
5A, lanes 6 and 7) yielded RPA signal
patterns that were clearly distinct from those of the prototype strains
He/80 and V (Fig. 5A, lanes 4 and 5). Intriguingly, analysis of stock
no. 61 revealed two overlapping RPA signal patterns (Fig. 5A, lane 8),
one similar to that of prototype He/80 and one similar to those of no.
62 and no. 66, suggesting coinfection with at least two viruses. Analysis of virus stock no. 102 (Fig. 5A, lane 9) revealed an RPA
signal pattern similar to that of prototype He/80 (Fig. 5A, lane 4) but
with distinct signal intensities, suggesting high sequence similarity
between the two strains. Direct sequencing of corresponding RT-PCR
amplification product indeed confirmed the complete identity of the two
viruses in the region of interest. The differences observed in the RPA
thus probably resulted from partial degradation of the archival RNA
from virus stock no. 102. The sequence of the M-G gene region in BDV
stock no. 62 revealed 17 nucleotide changes compared to that of the
prototype He/80 sequence. The deduced partial amino acid sequence of
the M protein in virus no. 62 was identical to that in He/80, whereas
the G protein of no. 62 harbored two amino acid substitutions (I143L and I144L).

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 5.
RPA analysis of a collection of standard stocks of BDV
He/80. (A) Samples of total RNA (10 µg) were prepared from rat brains
or C6 cell cultures infected with the following BDV He/80 stocks: no.
66, fifth passage in brains of newborn Lewis rats (lane 6); no. 62, fifth passage in brains of adult Lewis rats (lane 7); no. 61, fifth
passage in brains of newborn Lewis rats (lane 8); and no. 102, three
passages in brains of newborn Lewis rats and one subsequent passage in
the brain of an adult Lewis rat (lane 9). RNAs were analyzed by RPA
using high concentrations of RNase A, as described in the legend to
Fig. 1. Undigested RPA probe (lane 1). No specific products were
observed when the RPA was carried out with 10 µg of tRNA (lane 2) or
10 µg of total RNA from uninfected C6 cells (lane 3). RNA from C6
cells infected with BDV strains He/80 (lane 4) and V (lane 5) yielded
the expected characteristic signal patterns. (B) Corresponding RT-PCR
products of standard BDV He/80, virus stock no. 61, and virus stock no.
62 were incubated with (+) or without ( ) restriction enzyme
Bst11071, and products were visualized by agarose gel
electrophoresis and ethidium bromide staining. (C) Analysis of stock
no. 61 after one passage in the brains of six individual newborn
2m0/0 MRL mice (m1 to m6).
|
|
Despite the complex signal pattern observed with RNA of stock no.
61-infected rat brains, direct sequencing of corresponding
RT-PCR
amplification products from the M-G gene region revealed
complete
identity to stock no. 62 (data not shown), indicating
that viruses with
the latter sequence were predominant. To demonstrate
the existence of a
mixed virus population in stock no. 61, we
digested RT-PCR
amplification products of the M-G gene regions
of prototype He/80,
stock no. 62, and stock no. 61 with the restriction
enzyme
Bst110
7I, which cuts prototype He/80 but not
virus no.
62 (Fig.
5B). The RT-PCR product derived from stock no. 61 was
partially cleaved by
Bst110
7I (Fig.
5B),
supporting our previous
RPA results, which had suggested the presence
of small amounts
of He/80-like virus and large amounts of no. 62-like
virus.
To investigate whether one of the two virus variants might eventually
overgrow the other, we infected newborn mice with BDV
stock no. 61 by
the intracerebral route. Since stock no. 61 had
been generated by five
sequential passages in brains of newborn
rats, we assumed that this
deliberate change in animal hosts might
create a bottleneck situation,
which may favor replication of
the fitter virus variant. In fact, RPA
analysis of RNA from the
brains of the infected mice sacrificed at 4 weeks postinfection
revealed major changes in the signal patterns: the
no. 62-specific
RPA signals were now clearly dominant in all six mice,
whereas
the He/80-like signals showed markedly reduced intensities
(Fig.
5C).
 |
DISCUSSION |
In this study, we demonstrate that although BDV exhibits
extraordinary genetic stability under standard cell culture conditions, it is possible to isolate stable genetic virus variants from these cultures. Simple bottleneck situations under which the virus content of
single persistently infected cells was allowed to spread in uninfected
cell cultures yielded 1 culture out of 30 in which a virus variant
(designated 2/1) with two nucleotide exchanges in the G gene was stably
propagated. Since screening for new BDV variants was performed using a
diagnostic RPA that covered only about 1/18 of the viral genome, it is
reasonable to assume that additional cultures containing mutant viruses
with alterations outside the examined genome region were present. This
view is supported by the observation that virus spread was slow not
only in culture 2/1 but also in several other cultures of the
bottleneck experiment that propagated viruses with wild-type He/80
sequence in the examined M-G gene region. Because mutations in various locations of the viral genome can presumably contribute to such phenotypic changes, it remains unclear whether the mutations found in
the G gene of BDV variant 2/1, which result in a single-amino-acid change, are indeed responsible for the attenuated phenotype.
More than one virus was present in the original cell culture containing
BDV variant 2/1. As a consequence, most persistently infected cell
cultures resulting from infection with cell-free virus from 2/1 cells
did not propagate this mutant virus but rather viruses with the
wild-type genotype in the M-G gene region. A possible explanation for
the failure of virus variant 2/1 to propagate efficiently under these
experimental conditions is that its replication might be helper virus
dependent. Indeed, all efforts to obtain cell cultures propagating
exclusively virus variant 2/1 were unsuccessful. Since infection
experiments with high doses of cell-free virus from 2/1 cells did not
result in a preferential replication of the mutant virus, it seems not
to have properties of defective interfering particles.
We find it surprising that replication of virus variant 2/1 in the
original cell culture was apparently not affected by the wild-type-like
virus, which was simultaneously present. Since our experiments with
cell-free virus stocks clearly showed that the fitness of variant 2/1
is reduced, it remains to be explained why this handicap was not
disadvantageous under the conditions used in the bottleneck experiment.
It is possible that the cell-to-cell spread of BDV is mechanistically
distinct from the entry of cell-free virus into host cells and that the
defect of virus mutant 2/1 might selectively affect the latter pathway.
Supernatants of BDV-infected C6 cells contain only minute amounts of
cell-free infectious virus (23) (data not shown), suggesting
that direct cell-to-cell spread is the preferred mode of virus
propagation in this cell line.
An important result of this study was the finding that persistently
infected C6 cells are highly resistant to superinfection by other
strains of BDV. We believe that this biological property of BDV
contributes significantly to its genome stability, in addition to the
counterselection of newly generated variants with lower fitness within
the cell. Because BDV is noncytolytic and because it has no growth
inhibitory effect on persistently infected cells, resistance to
superinfection generates an ideal ecological niche for resident viruses
to produce progeny without competition by genetically distinct viruses
entering the cell from outside. The drawback of this situation is that
due to the lack of susceptible cells, novel BDV variants with increased
fitness cannot outgrow the resident virus population unless plenty of
uninfected cells are available. Such conditions can be generated
experimentally by enforcing bottleneck situations. In vivo, optimal
conditions for novel virus variants to outgrow the parental viruses
might exist during the first few weeks after infection of the central nervous system of a new host.
Superinfection interference was originally described for avian
retroviruses (33, 35) and was later also found to affect most noncytolytic mammalian retroviruses (36). Resistance to superinfection by retroviruses results from interaction of the env gene product of the endogenous virus with cellular
components that function as virus receptors, resulting in reduced
availability of virus entry mediators at the cell surface
(9). Superinfection interference has also been described for
other viruses, including noncytolytic variants of foot-and-mouth
disease virus (8) and measles virus (12). The
mechanisms of these restriction phenomena have not yet been elucidated.
Similarly, the mechanism of the BDV interference phenomenon that
we describe here is presently unknown. Preliminary studies showed
that it is not mediated by interferons or other soluble factors (M. Schwemmle and P. Staeheli, unpublished observation). When we used the
RPA to determine whether stocks of BDV He/80 with different passage
histories in brains of adult or newborn rats might contain viruses with
mutations in the M-G gene region, we found that only one of four stocks yielded the expected RPA signal pattern. Two stocks contained a BDV
variant that was about 2 to 3% different from prototype He/80.
Interestingly, the fourth virus stock contained a mixture of prototype
He/80 and the variant. Since all four virus stocks were generated from
the same starting material, it seems likely that the variant was
already present in that material and that it was selected from the
virus mixture with variable efficacy. In support of this view, we found
that one additional passage of the mixed virus stock in mouse brains
resulted in a preferential loss of the prototype He/80 strain. It is
possible that the new variant is a direct descendent of He/80 that
arose by mutation. Alternatively, the diseased horse from which He/80
was originally isolated might have been infected with two strains of
BDV. Because the sequence of the new virus variant closely resembles
that of prototype He/80 in some parts of the genome and that of
prototype strain V in others, it seems more likely that it represents a wild-type virus that evolved from a common ancestor of the Central European strains of BDV. In fact, Binz and coworkers (3)
presented evidence that simultaneous infection of horses with two
different genotypes of BDV is possible. It is tempting to speculate
that the various rat brain-derived He/80 virus stocks that contain different concentrations of "mouse-pathogenic" variant viruses may
have caused the reported variability of neurological symptoms in
experimentally infected mice (15, 26). This could explain, at least in part, the observation of Rubin et al. (26) that efficient replication of BDV in adult mice was only achieved after multiple passages of the initial rat-derived virus in mouse brains.
Sequence comparisons of the M-G gene region with database entries
showed that the new virus variant was almost identical to BDV isolate
RW98, which is believed to have originated from the blood of a
psychiatric patient (24, 25). This view was confirmed when
other genome regions of the variant were sequenced and compared to RW98
(30). This surprising finding, together with the fact that
the various BDV stocks analyzed in this study originated from the
laboratory in which RW98 was isolated, raises serious questions about a
human origin of this virus.
The results of this study are important for the correct interpretation
of epidemiological data. Because the genome stability of BDV in
persistently infected cell cultures is extraordinarily high, minor
sequence variations in virus isolates from human tissues were
previously regarded as solid proof that contamination with laboratory
strains had not occurred. Since accidental contamination presumably
occurs only at extremely low virus doses, it represents a situation
which strongly resembles the bottleneck condition applied in this
study. We have shown here that such conditions favor the outgrowth of
variant viruses.
 |
ACKNOWLEDGMENTS |
We thank Georg Kochs, Jürgen Hausmann, Juan Carlos de la
Torre, and Otto Haller for helpful comments on the manuscript.
This work was supported by grants from the Deutsche
Forschungsgemeinschaft and the Zentrum für Klinische Forschung I
of the Universitätsklinikum Freiburg. C.S. is a fellow of the
German Stipendienprogramm Infektionsforschung, DKFZ, Heidelberg.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Virology, University of Freiburg, Hermann-Herder-Strasse 11, D-79104 Freiburg, Germany. Fax: 49-761-203-6639. Phone:
49-761-203-6616. E-mail:
schwemm{at}ukl.uni-freiburg.de.
 |
REFERENCES |
| 1.
|
Berg, A. L., and M. Berg.
1998.
A variant form of feline Borna disease.
J. Comp. Pathol.
119:323-331[Medline].
|
| 2.
|
Berg, A. L.,
R. Dorries, and M. Berg.
1999.
Borna disease virus infection in racing horses with behavioral and movement disorders.
Arch. Virol.
144:547-559[CrossRef][Medline].
|
| 3.
|
Binz, T.,
J. Lebelt,
H. Niemann, and K. Hagenau.
1994.
Sequence analyses of the p24 gene of Borna disease virus in naturally infected horse, donkey and sheep.
Virus Res.
34:281-289[CrossRef][Medline].
|
| 4.
|
Briese, T.,
J. C. de la Torre,
A. Lewis,
H. Ludwig, and W. I. Lipkin.
1992.
Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells.
Proc. Natl. Acad. Sci. USA
89:11486-11489[Abstract/Free Full Text].
|
| 5.
|
Briese, T.,
M. Hornig, and W. I. Lipkin.
1999.
Bornavirus immunopathogenesis in rodents: models for human neurological diseases.
J. Neurovirol.
5:604-612[Medline].
|
| 6.
|
Cubitt, B.,
C. Oldstone, and J. C. de la Torre.
1994.
Sequence and genome organization of Borna disease virus.
J. Virol.
68:1382-1396[Abstract/Free Full Text].
|
| 7.
|
Czygan, M.,
W. Hallensleben,
M. Hofer,
S. Pollak,
C. Sauder,
T. Bilzer,
I. Blumcke,
P. Riederer,
B. Bogerts,
P. Falkai,
M. J. Schwarz,
E. Masliah,
P. Staeheli,
F. T. Hufert, and K. Lieb.
1999.
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders.
J. Infect. Dis.
180:1695-1699[CrossRef][Medline].
|
| 8.
|
de la Torre, J. C.,
M. Davila,
F. Sobrino,
J. Ortin, and E. Domingo.
1985.
Establishment of cell lines persistently infected with foot-and-mouth disease virus.
Virology
145:24-35[CrossRef][Medline].
|
| 9.
|
Delwart, E. L., and A. T. Panganiban.
1989.
Role of reticuloendotheliosis virus envelope glycoprotein in superinfection interference.
J. Virol.
63:273-280[Abstract/Free Full Text].
|
| 10.
|
Domingo, E., and J. J. Holland.
1997.
RNA virus mutations and fitness for survival.
Annu. Rev. Microbiol.
51:151-178[CrossRef][Medline].
|
| 11.
|
Dürrwald, R., and H. Ludwig.
1997.
Borna disease virus (BDV), a (zoonotic?) worldwide pathogen. A review of the history of the disease and the virus infection with comprehensive bibliography.
Zentbl. Veterinarmed. B
44:147-184.
|
| 12.
|
Fernandez-Munoz, R., and M. L. Celma.
1992.
Measles virus from a long-term persistently infected human T lymphoblastoid cell line, in contrast to the cytocidal parental virus, establishes an immediate persistence in the original cell line.
J. Gen. Virol.
73:2195-2202[Abstract/Free Full Text].
|
| 13.
|
Gonzalez-Dunia, D.,
C. Sauder, and J. C. de la Torre.
1997.
Borna disease virus and the brain.
Brain Res. Bull.
44:647-664[CrossRef][Medline].
|
| 14.
|
Gosztonyi, G., and H. Ludwig.
1995.
Borna disease-neuropathology and pathogenesis.
Curr. Top. Microbiol. Immunol.
190:39-73[Medline].
|
| 15.
|
Hallensleben, W.,
M. Schwemmle,
J. Hausmann,
L. Stitz,
B. Volk,
A. Pagenstecher, and P. Staeheli.
1998.
Borna disease virus-induced neurological disorder in mice: infection of neonates results in immunopathology.
J. Virol.
72:4379-4386[Abstract/Free Full Text].
|
| 16.
|
Hallensleben, W., and P. Staeheli.
1999.
Inhibition of Borna disease virus multiplication by interferon: cell line differences in susceptibility.
Arch. Virol.
144:1209-1216[CrossRef][Medline].
|
| 17.
|
Herzog, S., and R. Rott.
1980.
Replication of Borna disease virus in cell cultures.
Med. Microbiol. Immunol.
168:153-158[CrossRef][Medline].
|
| 18.
|
Holland, J.,
K. Spindler,
F. Horodyski,
E. Grabau,
S. Nichol, and S. VandePol.
1982.
Rapid evolution of RNA genomes.
Science
215:1577-1585[Abstract/Free Full Text].
|
| 19.
|
Iwata, Y.,
K. Takahashi,
X. Peng,
K. Fukuda,
K. Ohno,
T. Ogawa,
K. Gonda,
N. Mori,
S. Niwa, and S. Shigeta.
1998.
Detection and sequence analysis of borna disease virus p24 RNA from peripheral blood mononuclear cells of patients with mood disorders or schizophrenia and of blood donors.
J. Virol.
72:10044-10049[Abstract/Free Full Text].
|
| 20.
|
Jehle, C.,
W. I. Lipkin,
P. Staeheli,
R. M. Marion, and M. Schwemmle.
2000.
Authentic Borna disease virus transcripts are spliced less efficiently than cDNA-derived viral RNAs.
J. Gen. Virol.
81:1947-1954[Abstract/Free Full Text].
|
| 21.
|
Ludwig, H.,
L. Bode, and G. Gosztonyi.
1988.
Borna disease: a persistent virus infection of the central nervous system.
Prog. Med. Virol.
35:107-151[Medline].
|
| 22.
|
Nowonty, N.,
J. Kolodziejek,
C. Jehle,
A. Suchy,
P. Staeheli, and M. Schwemmle.
2000.
Isolation of a new subtype of Borna disease virus.
J. Virol.
74:5655-5658[Abstract/Free Full Text].
|
| 23.
|
Pauli, G., and H. Ludwig.
1985.
Increase of virus yields and releases of Borna disease virus from persistently infected cells.
Virus Res.
2:29-33[CrossRef][Medline].
|
| 24.
|
Planz, O.,
C. Rentzsch,
A. Batra,
H. J. Rziha, and L. Stitz.
1998.
Persistence of Borna disease virus-specific nucleic acid in blood of psychiatric patient.
Lancet
352:623[Medline].
|
| 25.
|
Planz, O.,
C. Rentzsch,
A. Batra,
T. Winkler,
M. Buttner,
H. J. Rziha, and L. Stitz.
1999.
Pathogenesis of borna disease virus: granulocyte fractions of psychiatric patients harbor infectious virus in the absence of antiviral antibodies.
J. Virol.
73:6251-6256[Abstract/Free Full Text].
|
| 26.
|
Rubin, S. A.,
R. W. D. Waltrip,
J. R. Bautista, and K. M. Carbone.
1993.
Borna disease virus in mice: host-specific differences in disease expression.
J. Virol.
67:548-552[Abstract/Free Full Text].
|
| 27.
|
Sauder, C., and J. C. de la Torre.
1999.
Cytokine expression in the rat central nervous system following perinatal Borna disease virus infection.
J. Neuroimmunol.
96:29-45[CrossRef][Medline].
|
| 28.
|
Schneider, P. A.,
T. Briese,
W. Zimmermann,
H. Ludwig, and W. I. Lipkin.
1994.
Sequence conservation in field and experimental isolates of Borna disease virus.
J. Virol.
68:63-68[Abstract/Free Full Text].
|
| 29.
|
Schwemmle, M.,
C. G. Hatalski,
A. J. Lewis, and W. I. Lipkin.
1999.
Borna Virus, p. 559-573.
In
R. Ahmed, and I. Chen (ed.), Persistent disease virus infection of the nervous system. John Wiley & Sons, New York, N.Y.
|
| 30.
|
Schwemmle, M.,
C. Jehle,
S. Formella, and P. Staeheli.
1999.
Sequence similarities between human bornavirus isolates and laboratory strains question human origin.
Lancet
354:1973-1974[CrossRef][Medline].
|
| 31.
|
Schwemmle, M.,
M. Salvatore,
L. Shi,
J. Richt,
C. Lee, and W. Lipkin.
1998.
Interactions of the Borna disease virus P, N, and X proteins and their functional implications.
J. Biol. Chem.
273:9007-9012[Abstract/Free Full Text].
|
| 32.
|
Stalder, A.,
A. Pagenstecher,
C. Kincaid, and I. Campbell.
1998.
Analysis of gene expression by multiprobe RNase protection assay.
Methods Mol. Med.
22:53-66.
|
| 33.
|
Steck, F. T., and H. Rubin.
1966.
The mechanism of interference between an avian leukosis virus and Rous sarcoma virus. I. Establishment of interference.
Virology
29:628-641[CrossRef][Medline].
|
| 34.
|
Stitz, L.,
B. Dietzschold, and K. M. Carbone.
1995.
Immunopathogenesis of Borna disease.
Curr. Top. Microbiol. Immunol.
190:75-92[Medline].
|
| 35.
|
Temin, H. M., and V. K. Kassner.
1975.
Replication of reticuloendotheliosis viruses in cell culture: chronic infection.
J. Gen. Virol.
27:267-274[Abstract/Free Full Text].
|
| 36.
|
Weiss, R. A.,
P. Clapham,
K. Nagy, and H. Hoshino.
1985.
Envelope properties of human T-cell leukemia viruses.
Curr. Top. Microbiol. Immunol.
115:235-346[Medline].
|
Journal of Virology, September 2000, p. 7878-7883, Vol. 74, No. 17
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Perez, M., Clemente, R., Robison, C. S., Jeetendra, E., Jayakar, H. R., Whitt, M. A., de la Torre, J. C.
(2007). Generation and Characterization of a Recombinant Vesicular Stomatitis Virus Expressing the Glycoprotein of Borna Disease Virus. J. Virol.
81: 5527-5536
[Abstract]
[Full Text]
-
Kolodziejek, J., Durrwald, R., Herzog, S., Ehrensperger, F., Lussy, H., Nowotny, N.
(2005). Genetic clustering of Borna disease virus natural animal isolates, laboratory and vaccine strains strongly reflects their regional geographical origin. J. Gen. Virol.
86: 385-398
[Abstract]
[Full Text]
-
Rauer, M., Gotz, J., Schuppli, D., Staeheli, P., Hausmann, J.
(2004). Transgenic Mice Expressing the Nucleoprotein of Borna Disease Virus in either Neurons or Astrocytes: Decreased Susceptibility to Homotypic Infection and Disease. J. Virol.
78: 3621-3632
[Abstract]
[Full Text]
-
Friedl, G., Hofer, M., Auber, B., Sauder, C., Hausmann, J., Staeheli, P., Pagenstecher, A.
(2004). Borna Disease Virus Multiplication in Mouse Organotypic Slice Cultures Is Site-Specifically Inhibited by Gamma Interferon but Not by Interleukin-12. J. Virol.
78: 1212-1218
[Abstract]
[Full Text]
-
Cotto, E., Neau, D., Cransac-Neau, M., Auriacombe, M., Pellegrin, J.-L., Ragnaud, J.-M., Fillet, A.-M., Belnard, M., Fleury, H., Lafon, M.-E.
(2003). Borna Disease Virus RNA in Immunocompromised Patients in Southwestern France. J. Clin. Microbiol.
41: 5577-5581
[Abstract]
[Full Text]
-
Geib, T., Sauder, C., Venturelli, S., Hassler, C., Staeheli, P., Schwemmle, M.
(2003). Selective Virus Resistance Conferred by Expression of Borna Disease Virus Nucleocapsid Components. J. Virol.
77: 4283-4290
[Abstract]
[Full Text]
-
Freude, S., Hausmann, J., Hofer, M., Pham-Mitchell, N., Campbell, I. L., Staeheli, P., Pagenstecher, A.
(2002). Borna Disease Virus Accelerates Inflammation and Disease Associated with Transgenic Expression of Interleukin-12 in the Central Nervous System. J. Virol.
76: 12223-12232
[Abstract]
[Full Text]
-
Ibrahim, M. S., Watanabe, M., Palacios, J. A., Kamitani, W., Komoto, S., Kobayashi, T., Tomonaga, K., Ikuta, K.
(2002). Varied Persistent Life Cycles of Borna Disease Virus in a Human Oligodendroglioma Cell Line. J. Virol.
76: 3873-3880
[Abstract]
[Full Text]
-
Pleschka, S., Staeheli, P., Kolodziejek, J., Richt, J. A., Nowotny, N., Schwemmle, M.
(2001). Conservation of coding potential and terminal sequences in four different isolates of Borna disease virus. J. Gen. Virol.
82: 2681-2690
[Abstract]
[Full Text]
-
Samuel, C. E.
(2001). Antiviral Actions of Interferons. Clin. Microbiol. Rev.
14: 778-809
[Abstract]
[Full Text]
-
Schamel, K., Staeheli, P., Hausmann, J.
(2001). Identification of the Immunodominant H-2Kk-Restricted Cytotoxic T-Cell Epitope in the Borna Disease Virus Nucleoprotein. J. Virol.
75: 8579-8588
[Abstract]
[Full Text]
-
Staeheli, P., Sentandreu, M., Pagenstecher, A., Hausmann, J.
(2001). Alpha/Beta Interferon Promotes Transcription and Inhibits Replication of Borna Disease Virus in Persistently Infected Cells. J. Virol.
75: 8216-8223
[Abstract]
[Full Text]